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Role of nutraceuticals in
hypolipidemic therapy
Carlo M. Barbagallo *, Angelo Baldassare Cefalù, Davide Noto and Maurizio R. Averna
Biomedical Department of Internal Medicine and Specialistics (DIBIMIS), University of Palermo, Palermo, Italy
Nutraceuticals are food components or active ingredients present in foods and used in
therapy. This article analyzes the characteristics of the molecules with a lipid-lowering
effect. The different nutraceuticals may have different mechanisms of action: inhibition
of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase
(policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor
activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols,
probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul).
Based on the different mechanisms of action, some nutraceuticals are then able to
enhance the action of statins. Nutraceuticals are often used without relevant evidence:
mechanisms of action are not clearly confirmed; most of clinical data are derived from
small, uncontrolled studies, and finally, except for fermented red rice, there are no clinical
trials which may document the relationship between these interventions and the reduction
of clinical events. Therefore, among all nutraceuticals, it is necessary to extrapolate
those having a really documentable efficacy. However, these kinds of treatments are
usually well-tolerated by patients. Overall, subjects with a middle or low cardiovascular
risk are the best indication of nutraceuticals, but they may also be useful for patients
experiencing side effects during classical therapies. Finally, in consideration of the additive
effect of some nutraceuticals, a combination therapy with classical drugs may improve
the achievement of clinical targets. Thus, nutraceuticals may be a helpful alternative
in hypolipidemic treatment and, if properly used, might represent a valid strategy of
cardiovascular prevention.
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Nutraceutics is an area of pharmacology regarding food components or active ingredients that
may be used as therapeutic agents. This includes a large number of compounds, such as an active
ingredient, food supplements (i.e., supplements the normal diet), and functional foods (i.e., foods
enriched with components with specific therapeutic or protective functions), as well as preparations
based on medicinal herbs. Most compounds are vegetable originated, but there are also substances
with animal origin (e.g., fish oil). Recent studies have shown promising results for these drugs in
various pathological complications such as diabetes, atherosclerosis, cardiovascular diseases, cancer,
and neurological disorders. These conditions involve many changes, including alterations redox
state, andmost of nutraceuticals have antioxidant activity with the ability to counteract this situation.
Hence, nutraceuticals are considered as sources of health promotion (1), and they, nowadays,
have received a considerable interest. A market research recently proposed that the worldwide
nutraceuticalsmarket is expanding andwould reachUS $250 billion by 2018 (1). Since nutraceuticals
are generally considered like “foods,” their use do not strictly follow the same rules of classical drugs
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TABLE 1 |Mechanisms of action of different hypothetical nutraceuticals with recommended lipid-lowering effect.
Hepatic cholesterol synthesis LDL uptake Intestinal cholesterol
absorption
Bile acids
metabolism
HMG-CoA reductase ACAT2 MTP PCSK9 BSH FXR
Policosanols #
Poliphenols # # #
Garlic # #
Probiotis # "
Plant sterols #
Guggul #
Berberine #
Red yeast rice #
HMG-CoA reductase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; ACAT2, acetyl-CoA acetyltransferase 2; MTP, microsomal transfer protein; PCSK9, proprotein convertase
subtilisin/kexin type 9; BSH, bile salt hydrolase; FXR, farnesoid X receptor.
and have not patent protection. Thus, a large amount of prepa-
rations have been suggested to have a therapeutic effect and are
rapidly available for patients. The process of market release for
a drug is a very lengthy process, starting from the “in vitro”
demonstration of the possible effects, followed by evaluation in
animalmodels and then in humans (in healthy volunteers first and
then in patientswith a specific disease) analyzing effectiveness and
tolerability of therapies (2). Following the approval and themarket
availability, there is also a strict monitoring of side effects. Large
controlled clinical trials will finally validate clinical outcomes.
In contrast, nutraceuticals are used in therapy without relevant
evidence. They might be involved in a wide variety of biological
processes, including activation of signal transduction pathways,
antioxidant defenses, gene expression, cell proliferation, differ-
entiation, and preservation of mitochondrial integrity, but the
mechanistic actions are not always fully clear and sometimes they
are not, or not particularly robust, for the theoretical basis of
their effectiveness. Clinical efficacy often derives only from data
produced by small-scale, uncontrolled studies. Thus, among all
nutraceuticals, it is necessary to extrapolate those having a really
documentable efficacy. Also, the “natural” origin does not protect
from side effects in itself, since many classical drugs derive from
plants and, in nature, there are also a number of toxic substances
(such as derived from mushrooms); moreover, the insufficient
clinical monitoring makes adverse events less predictable.
There are a variety of nutraceuticals with a potential lipid-
lowering effect (Table 1), and therefore useful in the cardiovas-
cular prevention (3). Nevertheless, in relation to the scarcity of
experimental studies, these molecules do not always have solid
scientific evidence with regard to both mechanisms of action and
clinical efficacy (4). Data produced by small studies were often
disavowed by larger and controlled studies or meta-analytic data.
Some nutraceuticals are also able to enhance the action of the
classic drugs (including statins), due to different mechanisms of
action. Finally, except for the red yeast rice, there are no clinical
trials which may document the relationship between any of these
treatments and the reduction of clinical events, and this represents
a great limit in their reasoned prescription (Table 2).
Here, we review the major nutraceuticals with lipid-lowering
effect: this should also include omega-3 polyunsaturated fatty
acids (fish oil), but the scientific history of this drug followed
TABLE 2 | Summary of clinical data of different nutraceuticals with
recommended lipid-lowering effect.
Lipid-lowering effects
hypothesized in
clinical studies
Effectiveness
confirmed in
controlled studies
Clinical
trials
Policosanols LDL-C ò about 25% No No
Poliphenols LDL-C ò up to 30% No No
Triglycerides ò about 40%
Garlic LDL-C ò 9–12% No No
Probiotis LDL-C ò up to 40% No No
Plant sterols LDL-C ò about 25% No No
Guggul LDL-C ò 5–15% Yes No
Berberine LDL-C ò 25%
Triglycerides ò 35%
Yes No
Red yeast rice LDL-C ò 20–30% Yes Yes
pathways different than that of other nutraceuticals, and therefore
will not be considered in this review.
Policosanols
These are a mixture of natural long chain aliphatic alcohols
obtained from a wide variety of plants. It has been suggested that
policosanols might inhibit the activity of HMG-CoA reductase,
but this is not definitively confirmed (5). In the early 90s, a number
of clinical studies suggested a lipid-lowering effect of policosanols
in different types of patients (healthy volunteers, hypercholes-
terolemics, diabetics, or postmenopausal women), with reduction
in LDL-cholesterol similar to that of statins (about 25%), and
a 10% increase of HDL-C (6). Some reports suggested benefits
even on clinical outcomes, including coronary ischemia or clau-
dication; these treatments appeared also very well tolerated by
patients (7, 8). Nevertheless, studies were of limited samples but
especially on a limited number of clinical centers, often in Cuba,
with reduction in LDL-cholesterol similar to that of statins (about
25%), and a 10% increase of HDL-C (9, 10).
Polyphenols
This is a very large family of substances available in the plant
world. The main feature is the presence of multiple pheno-
lic groups having a potent anti-oxidant effect; for this reason,
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polyphenols present in some foods typical of the Mediterranean
diet (olive oil, red wine, fruits, vegetables) are considered to
account for the protective effect of this nutritional model; drug
preparations, maybe for a different bioavailability, do not seem
to have the same clinical effect (11). It has also been postulated
that polyphenols are able to inhibit HMG-CoA reductase, as well
as ACAT2 and MTP, justifying a hypocholesterolemic effect (12).
Nevertheless, even if in an open study, Mollace and colleagues
have suggested the possibility of a great reduction of LDL-C
(>30%) and also triglycerides levels (>40%) with polyphenols
extracted from bergamot (13), a controlled study failed to demon-
strate any effect in subjects treated with two different polyphenols
(hesperidin and naringin) compared to a group on placebo (14).
Thus, the hypolipidemic effect of polyphenols still remains an
open question.
Garlic
Allicin, a substance contained in the bulb of garlic, seems to be
able to reduce both synthesis (perhaps through the inactivation
of HMG-CoA reductase) and intestinal absorption of choles-
terol (15), and therefore to have lipid-lowering properties, with
reductions of total cholesterol reported between 9 and 12% (16).
These data have recently been substantially refuted by Gardner
and colleagues: these authors, in a randomized placebo-controlled
trial, have not documented any cholesterol-lowering effect with
different formulations of garlic (17). Overall, garlic, even without
a significant lipid-lowering effect, could have other protective
effects on the cardiovascular system for its ability to reduce blood
pressure and platelet aggregation (18), but this needs to be better
investigated in large controlled trials.
Probiotics
They have received a lot of attention due to the potential
benefits that they seem to have in different fields. Regarding
lipid metabolism, probiotics could lower cholesterol absorption
through direct cellular effects or mediated by bile metabolism
(19). Several studies on different patients have documented signif-
icant reductions in total cholesterol, up to 40% (20–22). However,
exact mechanisms of action were not identified, and those pro-
posed (such as the inhibition of intestinal absorption of choles-
terol) are usually dependent on bacterial strains and methods of
execution of experiments, often very different from the “in vivo”
conditions. More recently, it has been postulated a role of expres-
sion of the gene of bile salt hydrolase activity in the lactobacilli
strains to explain the cholesterol-lowering action, even if this
hypothesis itself does not seem completely convincing (23). A
number of confounding factors, which also include local condi-
tions or functional anatomy, make complex the question and, at
the present time, additional data are certainly necessary to give a
definitive answer.
Guggul
This is a resin extracted from the bark of Commiphora mukul, a
small thorny tree, also known as the tree of myrrh, used medically
in India for hundreds of years (24). The active components,
guggulsterone E and Z, have been demonstrated to have an
antagonistic action of FXR, a nuclear receptor involved in the
bile metabolism. Based on this data, published in Science in 2002
(25), and given the close relationship between cholesterol and
bile metabolisms, it has been also proposed a role in modulating
plasma lipid levels. Different studies, mostly uncontrolled
trials, were conducted in India and showed a massive efficacy
of guggul in LDL-cholesterol levels reductions with no effect
on triglyceride or HDL-cholesterol concentrations (26). More
recently, a randomized placebo-controlled study in healthy
subjects with hyperlipidemia demonstrated no effect on plasma
lipids of guggul, which also caused allergic reactions in some
individuals as well (27), clarifying that guggul not only does
not seem to have a real lipid-lowering effect but it could also be
dangerous in predisposed individuals.
Plant Sterols
Plant sterols decrease intestinal absorption of cholesterol through
the reduction of the content of cholesterol within the micelles
and a consequent lower proportion of absorbable cholesterol
(28). In addition, some studies suggest that phytosterols are able
to compete with cholesterol in the carrier of the intracellular
incorporation (NPC1L1), and also increase the activity of trans-
membrane proteins responsible for the excretion of cholesterol
(ABCA1) and plant sterols (ABCG5 and ABCG8) in the intestine
and liver, with the net effect of increasing the release of both sterols
into the intestinal lumen by enterocytes and in the bile ducts in
the liver (29, 30). The lower intestinal absorption of cholesterol
induced by plant sterols decreases cholesterol pool of liver, which
responds by increasing the expression of LDL receptors, finally
resulting in higher uptake of plasma LDL and therefore in a net
hypocholesterolemic effect.
Formany years, there was a great interest in phytosterols, which
led to the development of a rich scientific literature. Phytosterols
have been added and investigated in different food carriers. Ini-
tially, they were tested in margarines but other carriers in which
it is possible to add plant sterols were subsequently identified:
oils, salad dressings,meat products, low-calorie beverages, cereals,
and finally drinks based on fermented milk (31–33). Clinical
studies with beverages based on fermented milk enriched with
phytosterols have shown that the effectiveness of phytosterols in
reducing cholesterol is almost equivalent to that obtained with
their introduction into margarine (34).
The cholesterol-lowering properties of phytosterols have been
documented in a series of clinical trials in different categories of
subjects: normolipidemic and hypercholesterolemic adults with
and without cardiovascular disease, patients with type 2 diabetes,
and children with familial hypercholesterolemia (35–39). In a
multicenter Italian study, 1.6 g phytosterols/day, taken with a
fermented milk, produced a reduction of LDL cholesterol from
166.2 2.0 to 147.4 2.8mg/dL, and at the same time had an
anti-oxidant effect, demonstrated by a significant reduction in
the levels of isoprostane (40). Overall, clinical data suggest that
the daily consumption of 1–3 g of plant sterols reduces LDL-
cholesterol by 5–15%, with no significant effects on HDL choles-
terol or triglycerides (41). Many clinical trials in patients with
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hypercholesterolemia treated with statins or fibrates are also avail-
able. The associations of plant sterols-fortified foods with these
drugs determine an additive effect on the reduction in plasma lev-
els of total cholesterol and LDL-cholesterol (41, 42). Some doubt,
however, remains on safety. Beyond a possible interference with
the absorption of fat-soluble vitamins, some observational studies
have suggested an independent association between plasma levels
of plant sterols and the risk of coronary heart disease. However,
in vivo studies in animals fed with high doses of plant sterols seem
to show a different effect, atherosclerosis, in terms of both, devel-
opment of new plaques and size or lipid accumulation of lesions
seem to improve (43). Recently, it has been suggested that the state
of cholesterol “absorber” (as opposed to the state of “synthesizer”)
may be the real atherogenic condition: thus, elevated plasma levels
of phytosterols should indicate a hyperabsorptive pattern which
might increase the risk (44). Longitudinal data in humans are
not conclusive, and therefore this issue appears far from solved
and the possibility of an increased of coronary risk, even if not
likely, remains a problem to keep into account during this kind of
treatment.
Berberine
This substance, with a bitter taste and intense yellow color, is
present in the bark, roots and stems, including underground (rhi-
zome) of plants of the genus Berberis, such as barberry (Berberis
vulgaris L.). For the antimicrobial and antisecretive properties,
berberin is traditionally used in the treatment of infections (45).
In recent years, most attentions have been on the metabolic prop-
erties of berberine. In 2004, Kong et al., have shown that berberine
reduced plasma cholesterol by 29%, triglycerides by 35%, and
LDL cholesterol by 25%, whereas did notmodify HDL-cholesterol
levels (46). Berberine increases the number of LDL receptors on
the hepatic cell surface, similarly to statins. However, during statin
therapy, the exposure of LDL-receptors on cell membranes follows
the decrease of the endogenous cholesterol synthesis and the
subsequent reduction of intracellular cholesterol pool, whereas the
action of berberine seems linked to the ability to inhibit a protein
(PCSK9) responsible for the partial degradation of LDL receptors
in the liver. For these reasons, berberine may have synergistic
effects with statins (47, 48). It is relevant to remember that inhibi-
tion of PCSK9 by monoclonal antibodies is a new lipid-lowering
strategy and several clinical trials are currently in progress (49,
50). Synergy between berberine and statins has been demon-
strated by both cell culture and experimental animals studies.
In humans, Bertolini et al. documented additive effects of treat-
ment with berberine/statins in patients with heterozygous familial
hypercholesterolemia, even higher to those of ezetimibe/statins;
a recent meta-analysis confirmed the cholesterol-lowering effect
of berberine, indicating also the necessity of further data from
randomized trials (51). Other studies have even highlighted hypo-
glycemic effects of berberine in patients with diabetes mellitus
type 2 by increasing the expression of insulin receptors and the
improving of insulin resistance (52). The action on PCSK9, the
ability to operate at multiple levels and the absence of significant
side effects, suggests that berberine represents one of the most
interesting available nutraceutic drugs.
Fermented Red Rice
The fermentation of red rice by a fungus (Monascus purpureus)
produces a substance called monacolin K, which inhibits the
synthesis of cholesterol (53). The monacolin K is also known as
lovastatin, a statin available in the market worldwide. The red
yeast rice also produces other monacolins that may enhance the
inhibition of HMG-CoA reductase. In addition, recent data show
that, compared to the classical lovastatin, monakolin K extracted
from red yeast rice have even a higher bioavailability with a higher
efficacy at the same dosage (54).
Red yeast rice represents an important drug of traditional Chi-
nese medicine, and a considerable amount of experimental data
have shown the efficacy and tolerability of red yeast rice. Heber
et al. in a controlled study in 83 healthy hyperlipidemic subjects
treated with 2.4 g/day of red yeast rice or placebo, observed large
reductions in LDL-cholesterol (39 19mg/dL), significantly dif-
ferent from placebo (55). Studies in other populations, as summa-
rized by Liu et al. in a meta-analysis of 93 randomized trials, led
to similar results, demonstrating a significant effect on total and
LDL-cholesterol levels but not on triglycerides orHDL-cholesterol
concentrations (56). In a study that evaluated the efficacy of
simvastatin (40mg/day) vs. alternative treatments (including red
yeast rice) for 12weeks in dyslipidemic subjects with a history
of statin myalgias, Becker et al. showed comparable reduction of
LDL-C in the two groups. These authors assessed also tolerability,
measured either as changes in biochemical parameters or pain
severity, and, behind the cholesterol lowering efficacy, observed
a good tolerability of red yeast rice (57). Red yeast rice was even
similar to pravastatin in the reduction of LDL-C (27 vs. 30%),
but it was associated with a lower rate of withdrawn from the
treatment (58). Overall, red yeast rice seems to have a lower
incidence of muscle disorders than statins. Myotoxicity, in the
form of myopathy, myalgia, myositis, or rhabdomyolysis, is the
most severe adverse effect of statins and the main cause of dis-
continuation. Statin therapy is associated with muscle problems
in approximately 10–25% of patients treated in clinical practice
(59). The exact pathophysiology of statin-induced myopathy is
not fully known, and multiple mechanisms may contribute to
that. One of these should be represented by a possible depletion
of mevalonate metabolites (such as ubiquinone), and red yeast
rice might be less efficient in blocking this metabolic cascade.
Psychological componentsmay also have a role, and the possibility
to replace statins with natural drugs may have the consequent
effect of removing this anxiety (60). Thus, red rice might be a real
therapeutic alternative in patients intolerant to statins. Recently,
in a group of hypercholesterolemic patients with a mild/moderate
risk previously intolerant to statins or refusing classical phar-
maceutical treatment, we examined in a double-blind, placebo-
controlled, randomized study, the efficacy, safety, and tolerability
of a product containing red yeast rice, but also the pulse wave
velocity as expression of arterial stiffness and endothelial function.
Patients received daily either a nutraceutical-combined pill, con-
taining red yeast rice 200mg (corresponding tomonakoline 3mg)
or placebo for 6weeks, and we observed, among subjects treated
with red yeast rise, a significative reduction of total cholesterol
and LDL-cholesterol (respectively by 10.4 and 12.2%), as well as
of pulse wave velocity (by 6.5%); triglyceride andHDL-cholesterol
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levels did not change. Safety parameters did not change during
the study and no patient reported muscle pain (61). Finally, in
a 5-year long secondary prevention trial in 5000 Chinese sub-
jects, Lu and colleagues demonstrated that an extract of red
yeast rice, the Xuenzhikang (XZK), beside a 20% decrease of
LDL-cholesterol, led to a significant reduction of coronary events
in comparison with placebo (5.7 vs. 10.4%), with a reduction
of relative and absolute risk of 45 and 4.7%, respectively, and
together with high tolerability of treatment (62). To date, this
unique trial of cardiovascular prevention with a nutracetical drug
is available.
Recent European Guidelines of cardiovascular prevention
include treatment with nutraceuticals for their clinical effects and
tolerability (63). However, it should be emphasized that some
categories of patients may particularly benefit from treatment
with nutraceuticals. The best indication is subjects with a middle
or lower cardiovascular risk in whom a modest reduction in
LDL-C may be sufficient to reach LDL-C levels internationally
recommended to reduce the risk (the so-called “target values”).
In these patients, usually only on dietary treatment, therapy with
nutraceuticals allows a better, rapid, and more stable achievement
of aims. Also, subjects experiencing side effects with statins may
be treated by nutraceuticals. In these subjects, a small but sta-
ble LDL-cholesterol reduction may be useful when statin ther-
apy at standard doses is not feasible. Another potential use of
those nutraceuticals having a mechanism of action different form
statins, e.g., berberin or plant sterols, is the combination therapy
with statins in order to either reduce statin dose or increase the
hypolipidemic efficacy. The clinical use of these preparations may
be also extended to other categories of patients. In those who are
afraid of side effects of classical drugs or simply do not want to
be considered a patient, the psychological effect of a “natural”
treatment may be helpful to permit to treat these subjects and
therefore to reduce their risk level. The cost issue raised by the
treatment with nutraceuticals is still unresolved, since these ther-
apies are usually more expensive than classical drugs and, in order
for them to be efficient in reducing cardiovascular risk, should be
lifelong.
In conclusion, nutraceuticals represent a valid alternative
hypolipidemic treatment, and thus have a role in cardiovascular
prevention strategies. Nutraceuticals have multiple physiological
benefits and their use may be a valid alternative or comple-
mentary therapy to conventional treatment in many fields. A
proper and reasoned use may help to prevent chronic diseases,
increase life expectancy, support the structure or function of the
body, delay the aging process, and help maintain overall good
health (64). Due to the growing industrial and commercial inter-
est in the future, it is desirable to have better regulations and
improve the scientific agreement to warrant safe usage and clinical
effectiveness (65).
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